Bomedemstat

Small molecule

Phase 3underway

Evidence outlook · registrational

Essential Thrombocythemia: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2027-07-14.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Essential Thrombocythemia
NCT06351631 · Merck Sharp & Dohme LLC
2024-05-23 – 2034-12-04 · Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
What this study did
NCT06456346 · Merck Sharp & Dohme LLC
2024-07-16 – 2028-03-24 · Essential Thrombocythemia
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT07722611 · Merck Sharp & Dohme LLC
2026-10-29 – 2032-11-30 · Polycythemia Vera
What this study did
Phase 2 (7)
Essential Thrombocythemia
NCT04262141 · Terrence J Bradley, MD
2020-10-02 – 2027-10-31 · Essential Thrombocythemia, Polycythemia Vera
What this study did
NCT04081220 · The University of Texas Health Science Center at San Antonio
2020-04-09 – 2026-12-20 · Thrombocythemia, Essential
What this study did
NCT04254978 · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
2020-09-08 – 2023-03-23 · Essential Thrombocythemia
What this study did
Other / comorbidity
NCT07424950 · United Lincolnshire Hospitals NHS Trust
2026-11-01 – 2029-11-01 · Myelofibrosis
What this study did
NCT05569538 · The University of Hong Kong
2022-12-01 – 2025-12-31 · Myelofibrosis
What this study did
NCT05558696 · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
2023-09-07 – 2025-07-10 · Polycythemia Vera
What this study did
NCT05223920 · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
2021-12-15 – 2024-08-22 · Thrombocythemia, Essential, Primary Myelofibrosis
What this study did
Phase 1/2 (3)
Essential Thrombocythemia
NCT03136185 · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
2017-07-18 – 2022-03-08 · Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF)
What this study did
Other / comorbidity
NCT05191797 · University of Washington
2022-04-11 – 2024-04-05 · Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
What this study did
NCT02842827 · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
2016-10-06 – 2018-10-30 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
Phase 1 (3)
Other / comorbidity
NCT05597306 · Terrence J Bradley, MD
2022-11-19 – 2026-11-19 · Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
What this study did
NCT07049939 · Merck Sharp & Dohme LLC
2025-08-20 – 2026-02-17 · Hepatic Insufficiency
What this study did
NCT06596668 · Merck Sharp & Dohme LLC
2024-10-02 – 2025-03-11 · Healthy
What this study did

Competitive landscape

This drug's own stage for Essential Thrombocythemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bomedemstat: this drugPhase 3Small moleculeLSD1 (lysine-specific demethylase 1)not yet gradedNo reviewed efficacy summary in this indication
Ropeginterferon Alfa-2b (Besremi)ApprovedProtein / enzyme therapeuticType I interferon receptorPartial signal
NCT04285086: Durable modified ELN response at months 9 and 12: 39 (43%) of 91 ropeginterferon alfa-2b vs five (6%) of 83 anagrelide
INCA033989Phase 3Monoclonal antibodymutant calreticulin (mutCALR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bomedemstat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
Phase 3Essential ThrombocythemiaActive not recruiting
Est. primary completion 2027-07-14 · NCT06079879 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Essential ThrombocythemiaActive not recruiting
Est. primary completion 2027-09-28 · NCT06456346 · CT.gov ↗
What to watch
2028 (1)
November 2028 (1)
Phase 2MyelofibrosisNot yet recruiting
Est. primary completion 2028-11-01 · NCT07424950 · CT.gov ↗
What to watch
2032 (1)
June 2032 (1)
Phase 2/3Polycythemia VeraRecruiting
Est. primary completion 2032-06-25 · NCT07722611 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 3Essential ThrombocythemiaRecruiting
Est. primary completion 2034-12-04 · NCT06351631 · CT.gov ↗
What to watch

See the full readout calendar ↗